The approval of momelotinib for the treatment of myelofibrosis represents a paradigm shift, demonstrating that hepcidin modulation can be a primary mechanism of action for a drug in a non-iron-overload disease. Here, HAMP is linked to Rare hereditary hemochromatosis.